Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. (2022)

First Author: Lin S

Attributed to: 'SPIICA' - the Sao Paulo-Imperial College Immune Correlates in Arbovirus Infection Network funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.17863/cam.82533

Publication URI: https://www.repository.cam.ac.uk/handle/1810/335091

Type: Other